Sulfonylureas (SUs) were originally introduced in the therapy of T2DM in the 1950s; however, they are still considered as the second‑most prescribed class of antidiabetic drugs, following metformin.[2] Treatment with SUs gifts certain advantages, with the most prominent being low cost, efficacy, and vast experience after many years of usage. Still, there are particular concerns related to SUs therapy, including side effects – mainly hypoglycemia and weight gain – and lack of long‑term efficiency (due to beta‑cell exhaustion provoked by the insulin‑secreting mechanism of their action). Most importantly, CV safety of the class has been questioned by various studies, with evidence derived from meta‑analyses pointing toward an association between SUs use, increased mortality, and a higher risk for stroke.